Clinical Trials Logo

Functional Dyspepsia clinical trials

View clinical trials related to Functional Dyspepsia.

Filter by:

NCT ID: NCT05842408 Not yet recruiting - Clinical trials for Functional Dyspepsia

Phase III Clinical Trial of DA-5212 in Patients With Functional Dyspepsia

Start date: May 2023
Phase: Phase 3
Study type: Interventional

This study is to evaluate efficacy and safety of DA-5212 in patients with functional dyspepsia

NCT ID: NCT05836597 Recruiting - Clinical trials for Functional Dyspepsia

Functional Dyspepsia Treatment Using Virtual Reality

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effectiveness of using virtual reality to treat gastrointestinal symptoms related to functional dyspepsia.

NCT ID: NCT05827575 Recruiting - Clinical trials for Functional Dyspepsia

Transcutaneous Auricular Vagal Nerve Stimulation for Functional Dyspepsia With Sleep Disturbances: a Randomized Controlled Trial

Start date: March 30, 2022
Phase: N/A
Study type: Interventional

Functional dyspepsia(FD) is most common in functional gastrointestinal disorders whose rick factors include sleep disturbances. The medication treatment for functional dyspepsia with sleep disturbances has disadvantages such as addiction and withdrawal symptoms. Transcutaneous auricular vagal nerve stimulation(taVNS) is a new therapeutic method to improve dyspepsia and sleep. Study on taSNS for FD with sleep disturbances has not yet been explored.

NCT ID: NCT05812339 Enrolling by invitation - Gastroparesis Clinical Trials

Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls

Start date: November 1, 2022
Phase:
Study type: Observational

This is an analytical validation observational cohort study is designed to provide evidence of: safety and reliability of Body Surface Gastric Mapping using the Gastric Alimetry System (GAS), normal reference values, and correlation of metrics with patient symptoms among healthy adults and patients diagnosed with upper abdominal motility disorders. GAS is intended to record, store, view and process gastric myoelectrical activity. This is a proprietary system consisting of multiple electrodes arranged on an array that is placed precisely over the stomach, a reader to collect the electrode measurements and a smart tablet application to track patient reported symptoms. Participants meeting inclusion and exclusion criteria will continue fasting for 30 minutes after the Gastric Alimetry System has been applied and begun measuring, eat a standard study meal within 10 minutes and remain quietly seated, reclining, for 4 hours as the GAS continues to collect data. The array is removed and the abdomen is examined for evidence of skin effects.

NCT ID: NCT05810805 Not yet recruiting - Clinical trials for Inflammatory Bowel Diseases

Measurement and Analysis of Gas Composition in Digestive Tract

Start date: April 1, 2023
Phase:
Study type: Observational

The purpose of this study is to detect the concentration of various gases,including hydrogen, methane, hydrogen sulfide, nitric oxide in different parts of the digestive tract by a safe and direct method, and to establish a human digestive tract gas profiles. Analyze the differences in gas components in different segments of the digestive tract in patients with different diseases, and analyze the correlation between specific gases and digestive tract diseases and non-specific symptoms.

NCT ID: NCT05693259 Completed - Clinical trials for Functional Dyspepsia

Improvement of Functional Dyspepsia After Drinking Alkaline Ionized Water From Alkaline Ionizer

Start date: August 10, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the effect of drinking electrolyzed alkaline reduced water (EARW) compared to drinking purified water (PW) on functional dyspepsia (FD) patients. The main question[s] it aims to answer are: - Drinking EARW (EARW group) will alleviate gastrointestinal (GI) symptoms and FD symptoms compared to drinking PW (PW group). - Drinking EARW will make higher the FD-related Quality of Life (FD-QOL) compared to drinking PW. Patients will drink EARW 10mL/kg/day body weight for 6 weeks according to the instruction of researcher using the experimental device installed at each patient's house. After 6 week, EARW and PW groups will be compared to evaluate effect of GI symptom and FD-related QOL.

NCT ID: NCT05687539 Recruiting - Clinical trials for Functional Dyspepsia

Mastiha or Mastiha Water in Functional Dyspepsia

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The main aim of this study is to establish whether Mastiha products ameliorate functional dyspepsia symptoms.

NCT ID: NCT05666154 Recruiting - Clinical trials for Functional Dyspepsia

Confocal Laser Endomicroscopy Based Diet in Functional Dyspepsia

CLEFD
Start date: December 5, 2021
Phase: N/A
Study type: Interventional

After a thorough baseline evaluation, functional dyspepsia (FD) patients will be exposed to nutrients while undergoing confocal laser endomicroscopy (CLE). Patients presenting an acute mucosal reaction upon nutrient exposure will be instructed to exclude their respective trigger nutrient or a nutrient without mucosal reaction (=sham diet) from their diet for 4 weeks in a randomized, blinded crossover fashion. The aim of the trial is to assess the symptomatic response to the targeted diet and further elucidate mechanisms underlying the acute mucosal reactions observed in CLE upon nutrient exposure.

NCT ID: NCT05655819 Recruiting - Clinical trials for Functional Dyspepsia

A Study of Glutamine to Treat Intestinal Permeability in Functional Dyspepsia

Start date: February 16, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this research is to collect data from patients diagnosed with functional dyspepsia who are treated with glutamine and describe safety and treatment results compared to patients taking a placebo. Glutamine, an essential amino acid in humans, is an important energy source for cells lining the gastrointestinal tract and has been shown to play an important role in regulating the strength of the intestinal wall.

NCT ID: NCT05653310 Enrolling by invitation - Clinical trials for Functional Dyspepsia

Tradipitant for Functional Dyspepsia

Start date: February 9, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the effects of tradipitant relative to placebo on gastric motor functions, satiation, and postprandial symptoms in patients with functional dyspepsia.